ResearcherKanagawa University of Human ServicesActive in the last 2 years
Hiroto Narimatsu
Matched on ORCID iD 0000-0002-0383-4911; OpenAlex author ID A5087679758. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 22
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 4
- Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. Last author DOI 10.1002/cam4.71233↗
- Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. Last author DOI 10.3389/frhs.2024.1275496↗
- Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysi… Co-author DOI 10.1001/jamanetworkopen.2021.45515↗
- Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yuriko Sasahara · 3 shared papers, 2022–2025 · strength 0.74
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Paper Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. DOI 10.3389/frhs.2024.1275496↗
- Yuki Takumoto · 3 shared papers, 2022–2025 · strength 0.74
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Paper Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. DOI 10.3389/frhs.2024.1275496↗
- Manabu Akazawa · 3 shared papers, 2022–2025 · strength 0.74
- Paper Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. DOI 10.1002/cam4.71233↗
- Paper Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Sy… DOI 10.1001/jamanetworkopen.2021.45515↗
- Paper Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. DOI 10.3389/frhs.2024.1275496↗
- Takashi Yoshioka · 1 shared paper, 2024 · strength 0.19
- Kumiko Umemoto · 1 shared paper, 2024 · strength 0.19
- Hiroyuki Takeda · 1 shared paper, 2024 · strength 0.19
- Makoto Ueno · 1 shared paper, 2024 · strength 0.19
- Yu Sunakawa · 1 shared paper, 2024 · strength 0.19
- Akira Fukutomi · 1 shared paper, 2020 · strength 0.08
- Shoji Nakamori · 1 shared paper, 2020 · strength 0.08
- Amane Takahashi · 1 shared paper, 2020 · strength 0.08
- Yuji Kaneoka · 1 shared paper, 2020 · strength 0.08
- Masato Nagino · 1 shared paper, 2020 · strength 0.08
- Narikazu Boku · 1 shared paper, 2020 · strength 0.08
- Keita P. Mori · 1 shared paper, 2020 · strength 0.08
- Naohiro Sata · 1 shared paper, 2020 · strength 0.08
- Katsuhiko Uesaka · 1 shared paper, 2020 · strength 0.08
- Hirochika Toyama · 1 shared paper, 2020 · strength 0.08
- Yukiyasu Okamura · 1 shared paper, 2020 · strength 0.08
- Soichiro Morinaga · 1 shared paper, 2020 · strength 0.08
- Satoshi Hirano · 1 shared paper, 2020 · strength 0.08
- Akio Yanagisawa · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.